456 related articles for article (PubMed ID: 29558283)
1. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply.
Bell A; Bennett AS; Jones TS; Doe-Simkins M; Williams LD
Subst Abus; 2019; 40(1):52-55. PubMed ID: 29558283
[No Abstract] [Full Text] [Related]
2. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
[TBL] [Abstract][Full Text] [Related]
3. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
Fairbairn N; Coffin PO; Walley AY
Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187
[TBL] [Abstract][Full Text] [Related]
4. Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data.
Mahonski SG; Leonard JB; Gatz JD; Seung H; Haas EE; Kim HK
Clin Toxicol (Phila); 2020 Feb; 58(2):117-123. PubMed ID: 31092050
[No Abstract] [Full Text] [Related]
5. Higher doses of naloxone are needed in the synthetic opiod era.
Moss RB; Carlo DJ
Subst Abuse Treat Prev Policy; 2019 Feb; 14(1):6. PubMed ID: 30777088
[TBL] [Abstract][Full Text] [Related]
6. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs.
Kim HK; Connors NJ; Mazer-Amirshahi ME
Expert Opin Drug Saf; 2019 Jun; 18(6):465-475. PubMed ID: 31033357
[TBL] [Abstract][Full Text] [Related]
7. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids.
Dahan A; Franko TS; Carroll JW; Craig DS; Crow C; Galinkin JL; Garrity JC; Peterson J; Rausch DB
Front Public Health; 2024; 12():1346109. PubMed ID: 38481848
[TBL] [Abstract][Full Text] [Related]
8. Community-Based Response to Fentanyl Overdose Outbreak, San Francisco, 2015.
Rowe C; Wheeler E; Stephen Jones T; Yeh C; Coffin PO
J Urban Health; 2019 Feb; 96(1):6-11. PubMed ID: 29725887
[TBL] [Abstract][Full Text] [Related]
9. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
[TBL] [Abstract][Full Text] [Related]
10. Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021.
Rock P; Slavova S; Westgate PM; Nakamura A; Walsh SL
Drug Alcohol Depend; 2024 Feb; 255():111062. PubMed ID: 38157702
[TBL] [Abstract][Full Text] [Related]
11. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
[TBL] [Abstract][Full Text] [Related]
12. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Fentanyl Overdose - Massachusetts, 2014-2016.
Somerville NJ; O'Donnell J; Gladden RM; Zibbell JE; Green TC; Younkin M; Ruiz S; Babakhanlou-Chase H; Chan M; Callis BP; Kuramoto-Crawford J; Nields HM; Walley AY
MMWR Morb Mortal Wkly Rep; 2017 Apr; 66(14):382-386. PubMed ID: 28406883
[TBL] [Abstract][Full Text] [Related]
14. The need for multiple naloxone administrations for opioid overdose reversals: A review of the literature.
Abdelal R; Banerjee AR; Carlberg-Racich S; Darwaza N; Ito D; Epstein J
Subst Abus; 2022; 43(1):774-784. PubMed ID: 35112993
[No Abstract] [Full Text] [Related]
15. Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018-December 2019.
O'Donnell J; Gladden RM; Kariisa M; Mattson CL
Addiction; 2022 May; 117(5):1483-1490. PubMed ID: 34882865
[TBL] [Abstract][Full Text] [Related]
16. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose.
Krotulski AJ; Chapman BP; Marks SJ; Ontiveros ST; Devin-Holcombe K; Fogarty MF; Trieu H; Logan BK; Merchant RC; Babu KM
Clin Toxicol (Phila); 2022 Feb; 60(2):197-204. PubMed ID: 34278904
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019.
Jiang X; Guy GP; Dunphy C; Pickens CM; Jones CM
Drug Alcohol Depend; 2021 Dec; 229(Pt A):109160. PubMed ID: 34740067
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments.
Miner NB; Schutzer WE; Zarnegarnia Y; Janowsky A; Torralva R
Drug Alcohol Depend; 2021 Oct; 227():108974. PubMed ID: 34492557
[TBL] [Abstract][Full Text] [Related]
19. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review.
Moe J; Godwin J; Purssell R; O'Sullivan F; Hau JP; Purssell E; Curran J; Doyle-Waters MM; Brasher PMA; Buxton JA; Hohl CM
CJEM; 2020 Mar; 22(2):178-186. PubMed ID: 31955714
[TBL] [Abstract][Full Text] [Related]
20. Naloxone interventions in opioid overdoses: a systematic review protocol.
Shaw LV; Moe J; Purssell R; Buxton JA; Godwin J; Doyle-Waters MM; Brasher PMA; Hau JP; Curran J; Hohl CM
Syst Rev; 2019 Jun; 8(1):138. PubMed ID: 31186071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
